Cross-genotype-specific T-cell responses in acute hepatitis e virus (HEV) infection

Journal of Viral Hepatitis

Volumn 23, Issue 4, 2016, Pages 305-315

  Gisa, A ^a   Suneetha, P V ^a   Behrendt, P ^a   Pischke, S ^a,b   Bremer, B ^a   Falk, C S ^a   Manns, M P ^a   Cornberg, M ^a,c   Wedemeyer, H ^a,c   Kraft, A R M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Center for Experimental and Clinical Infection Research   (Germany)

Author keywords

cellular immune response; cross genotype; hepatitis; hepatitis E virus (HEV); T cell

Indexed keywords

ALANINE AMINOTRANSFERASE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HEPATITIS E VIRUS GENOTYPE 1; HEPATITIS E VIRUS GENOTYPE 3; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VIRAL CLEARANCE; BLOOD; CLASSIFICATION; CROSS REACTION; DNA SEQUENCE; HETEROLOGOUS IMMUNITY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; T LYMPHOCYTE;

ADULT; AGED; ALANINE TRANSAMINASE; CROSS REACTIONS; CYTOKINES; FEMALE; GENOTYPE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNOLOGIC MEMORY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES;

EID: 84960409631     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12495     Document Type: Article

References (48)

1. Holla RP, Ahmad I, Ahmad Z, Jameel S,. Molecular virology of hepatitis E virus. Semin Liver Dis 2013; 33 (1): 3-14.
2. Wedemeyer H, Pischke S, Manns MP,. Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology 2012; 142 (6): 1388-1397.e1.
3. Sayed IM, Vercouter AS, Abdelwahab SF, Vercauteren K, Meuleman P,. Is HEV an emerging problem in industrialized countries? Hepatology 2015; 62 (6): 1883-1892.
4. Behrendt P, Steinmann E, Manns MP, Wedemeyer H,. The impact of hepatitis E in the liver transplant setting. J Hepatol 2014; 61 (6): 1418-1429.
5. Zhang X, Wei M, Pan H, et al,. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in hecolin((R)). Vaccine 2014; 32 (32): 4039-4050.
6. Zhu FC, Zhang J, Zhang XF, et al,. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376 (9744): 895-902.
7. Zhang J, Zhang XF, Huang SJ, et al,. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 2015; 372 (10): 914-922.
8. Zhang Y, Zeng H, Liu P, et al,. Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission. Vaccine 2015; 33 (38): 4922-4928.
9. Huang W, Zhang H, Harrison TJ, Lang S, Huang G, Wang Y,. Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. J Med Virol 2008; 80 (5): 824-832.
10. Meng XJ,. Hepatitis E virus: animal reservoirs and zoonotic risk. Vet Microbiol 2010; 140 (3-4): 256-265.
11. Kamar N, Bendall R, Legrand-Abravanel F, et al,. Hepatitis E. Lancet 2012; 379 (9835): 2477-2488.
12. Pischke S, Behrendt P, Bock CT, Jilg W, Manns MP, Wedemeyer H,. Hepatitis E in germany-an under-reported infectious disease. Dtsch Arztebl Int. 2014; 111 (35-36): 577-583.
13. Krumbholz A, Joel S, Dremsek P, et al,. Seroprevalence of hepatitis E virus (HEV) in humans living in high pig density areas of germany. Med Microbiol Immunol 2014; 203 (4): 273-282.
14. Krumbholz A, Joel S, Neubert A, et al,. Age-related and regional differences in the prevalence of hepatitis E virus-specific antibodies in pigs in germany. Vet Microbiol 2013; 167 (3-4): 394-402.
15. Hewitt PE, Ijaz S, Brailsford SR, et al,. Hepatitis E virus in blood components: a prevalence and transmission study in southeast england. Lancet 2014; 384 (9956): 1766-1773.
16. Kamar N, Selves J, Mansuy JM, et al,. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358 (8): 811-817.
17. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S,. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361 (10): 1025-1027.
18. Pischke S, Stiefel P, Franz B, et al,. Chronic hepatitis e in heart transplant recipients. Am J Transplant 2012; 12 (11): 3128-3133.
19. Pischke S, Greer M, Hardtke S, et al,. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. Transpl Infect Dis 2014; 16 (2): 333-339.
20. Pischke S, Hardtke S, Bode U, et al,. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int 2013; 33 (5): 722-726.
21. Kamar N, Mallet V, Izopet J,. Ribavirin for chronic hepatitis E virus infection. N Engl J Med 2014; 370 (25): 2447-2448.
22. Kamar N, Izopet J, Tripon S, et al,. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014; 370 (12): 1111-1120.
23. Peron JM, Abravanel F, Guillaume M, et al,. Treatment of autochthonous acute hepatitis e with short term ribavirin: a multicenter retrospective study. Liver Int 2015; doi: 10.111/liv12911.
24. Debing Y, Gisa A, Dallmeier K, et al,. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 2014; 147 (5): 1008-1011.
25. van Eijk JJ, Madden RG, van der Eijk AA, et al,. Neuralgic amyotrophy and hepatitis E virus infection. Neurology 2014; 82 (6): 498-503.
26. van den Berg B, van der Eijk AA, Pas SD, et al,. Guillain-barre syndrome associated with preceding hepatitis E virus infection. Neurology 2014; 82 (6): 491-497.
27. Pischke S, Behrendt P, Manns MP, Wedemeyer H,. HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. Lancet Infect Dis. 2014; 14 (8): 678-679.
28. Ward S, Lauer G, Isba R, Walker B, Klenerman P,. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol 2002; 128 (2): 195-203.
29. Rehermann B,. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009; 119 (7): 1745-1754.
30. Lauer GM, Lucas M, Timm J, et al,. Full-breadth analysis of CD8 + T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005; 79 (20): 12979-12988.
31. Galal IF, Zakaria Z, Allam WR, et al,. Cross reactive cellular immune response to HCV genotype 1 and 4 antigens among genotype 4 exposed subjects. PLoS One 2014; 9 (6): e101264.
32. Giugliano S, Oezkan F, Bedrejowski M, et al,. Degree of cross-genotype reactivity of hepatitis C virus-specific CD8 + T cells directed against NS3. Hepatology 2009; 50 (3): 707-716.
33. Tripathy AS, Das R, Rathod SB, Arankalle VA,. Cytokine profiles, CTL response and T cell frequencies in the peripheral blood of acute patients and individuals recovered from hepatitis E infection. PLoS One 2012; 7 (2): e31822.
34. Aggarwal R, Shukla R, Jameel S, et al,. T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat. 2007; 14 (4): 283-292.
35. Wedemeyer H, Rybczynska J, Pischke S, Krawczynski K,. Immuno-pathogenesis of hepatitis E virus infection. Semin Liver Dis 2013; 33 (1): 71-78.
36. Husain MM, Aggarwal R, Kumar D, Jameel S, Naik S,. Effector T cells immune reactivity among patients with acute hepatitis E. J Viral Hepat. 2011; 18 (10): e603-e608.
37. Suneetha PV, Pischke S, Schlaphoff V, et al,. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012; 55 (3): 695-708.
38. Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR,. A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. J Virol Methods 2006; 131 (1): 65-71.
39. Suneetha PV, Schlaphoff V, Wang C, et al,. Effect of peptide pools on effector functions of antigen-specific CD8 + T cells. J Immunol Methods 2009; 342 (1-2): 33-48.
40. Zhou Y, Callendret B, Xu D, et al,. Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 2012; 209 (8): 1481-1492.
41. Feng Z, Lemon SM,. Peek-a-boo: membrane hijacking and the pathogenesis of viral hepatitis. Trends Microbiol 2014; 22 (2): 59-64.
42. Feng Z, Li Y, McKnight KL, et al,. Human pDCs preferentially sense enveloped hepatitis A virions. J Clin Invest. 2015; 125 (1): 169-176.
43. Ramdasi AY, Arya RP, Arankalle VA,. Effect of pregnancy on anti-HEV antibody titres, plasma cytokines and the corresponding gene expression levels in the PBMCs of patients presenting with self-recovering clinical and subclinical hepatitis E. PLoS One 2014; 9 (8): e103257.
44. Grebely J, Feld JJ, Applegate T, et al,. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; 57 (6): 2124-2134.
45. Purcell RH, Nguyen H, Shapiro M, et al,. Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 2003; 21 (19-20): 2607-2615.
46. Sanford BJ, Opriessnig T, Kenney SP, Dryman BA, Cordoba L, Meng XJ,. Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs. Vaccine 2012; 30 (44): 6249-6255.
47. Sanford BJ, Dryman BA, Huang YW, Feagins AR, Leroith T, Meng XJ,. Prior infection of pigs with a genotype 3 swine hepatitis E virus (HEV) protects against subsequent challenges with homologous and heterologous genotypes 3 and 4 human HEV. Virus Res 2011; 159 (1): 17-22.
48. Liu P, Du R, Wang L, et al,. Management of hepatitis E virus (HEV) zoonotic transmission: protection of rabbits against HEV challenge following immunization with HEV 239 vaccine. PLoS One 2014; 9 (1): e87600.